ESMO CONGRESS 2022
![ESMO CONGRESS 2022](/images/conferences/esmo-congress-2022_big.png)
Programme du congrès
Highlights on cabozantinib with nivo and ipi for intermediate_poor risk adv. RCC_COSMIC-313
![Highlights on cabozantinib with nivo and ipi for intermediate_poor risk adv. RCC_COSMIC-313 Highlights on cabozantinib with nivo and ipi for intermediate_poor risk adv. RCC_COSMIC-313](/images/videos/highlights-on-cabozantinib-with-nivo-and-ipi-for-intermediate-poor-risk-adv-rcc-cosmic-313_20220915103825.png)
- Date : 14/09/2022
- 21
1
Highlights on ADT duration with post-operative radiotherapy in prostate cancer_RADICALS-HD
![Highlights on ADT duration with post-operative radiotherapy in prostate cancer_RADICALS-HD Highlights on ADT duration with post-operative radiotherapy in prostate cancer_RADICALS-HD](/images/videos/highlights-on-adt-duration-with-post-operative-radiotherapy-in-prostate-cancer-radicals-hd_20220915103616.png)
- Date : 14/09/2022
- 16
0
Highlights on first-line atezolizumab in NSCLC not eligible for platinum_ The IPSOS study
![Highlights on first-line atezolizumab in NSCLC not eligible for platinum_ The IPSOS study Highlights on first-line atezolizumab in NSCLC not eligible for platinum_ The IPSOS study](/images/videos/highlights-on-first-line-atezolizumab-in-nsclc-not-eligible-for-platinum-the-ipsos-study_20220915103918.png)
- Date : 14/09/2022
- 15
0
Highlights on Sotorasib in NSCLC with KRAS G12C mutation_ The CodeBreaK 200 study
![Highlights on Sotorasib in NSCLC with KRAS G12C mutation_ The CodeBreaK 200 study Highlights on Sotorasib in NSCLC with KRAS G12C mutation_ The CodeBreaK 200 study](/images/videos/highlights-on-sotorasib-in-nsclc-with-kras-g12c-mutation-the-codebreak-200-study_20220929134914.png)
- Date : 14/09/2022
- 9
0
Highlights on neoadj. vs adjuvant pembrolizumab in resected stage III-IV melanoma_SWOG S1801
![Highlights on neoadj. vs adjuvant pembrolizumab in resected stage III-IV melanoma_SWOG S1801 Highlights on neoadj. vs adjuvant pembrolizumab in resected stage III-IV melanoma_SWOG S1801](/images/videos/highlights-on-neoadj-vs-adjuvant-pembrolizumab-in-resected-stage-iii-iv-melanoma-swog-s1801_20220922103800.png)
- Date : 14/09/2022
- 8
0
Highlights on the efficacy and safety of fruquintinib in refractory mCRC_ The FRESCO-2 study
![Highlights on the efficacy and safety of fruquintinib in refractory mCRC_ The FRESCO-2 study Highlights on the efficacy and safety of fruquintinib in refractory mCRC_ The FRESCO-2 study](/images/videos/highlights-on-the-efficacy-and-safety-of-fruquintinib-in-refractory-mcrc-the-fresco-2-study_20220929134950.png)
- Date : 14/09/2022
- 8
0
Highlights on pembrolizumab with CRT in locally advanced HNSCC_ The KEYNOTE-412 study
![Highlights on pembrolizumab with CRT in locally advanced HNSCC_ The KEYNOTE-412 study Highlights on pembrolizumab with CRT in locally advanced HNSCC_ The KEYNOTE-412 study](/images/videos/highlights-on-pembrolizumab-with-crt-in-locally-advanced-hnscc-the-keynote-412-study_20220922104544.png)
- Date : 14/09/2022
- 6
0